FDAnews
www.fdanews.com/articles/84561-avant-announces-start-of-clinical-trial-of-typhoid-fever-vaccine

AVANT ANNOUNCES START OF CLINICAL TRIAL OF TYPHOID FEVER VACCINE

February 14, 2006

Avant Immunotherapeutics has launched a placebo-controlled, double-blind Phase I/II study of its typhoid fever vaccine candidate, Ty800. The clinical trial, sponsored by the NIH, is being conducted at the Cincinnati Children's Hospital Medical Center.

The study is an in-patient dose-escalating clinical trial aimed at determining the safety and immunogenicity of the single-dose, oral Ty800 vaccine. The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult volunteers and will follow each subject for six months post-vaccination. The trial seeks to confirm the safety and immunogenicity of the Ty800 vaccine observed in an earlier physician-sponsored Ty800 vaccine study.